¹⁷⁷Lu-labeled manganese-doped mesoporous hydroxyapatite microspheres for enhanced tumor in situ vaccination

By Ivan Penuelas

Tumor in situ vaccination (ISV) strategies, which involve the release of tumor antigens through local radiotherapy and intratumoral adjuvant injections, have shown promise in clinical trials. However, achieving a sustainable immune response remains challenging.

A recent study introduces an enhanced ISV method using ¹⁷⁷Lu-labeled manganese-doped mesoporous hydroxyapatite (¹⁷⁷Lu/Mn-HAP) microspheres that induce immunogenic cell death (ICD) in tumor cells (Xu et al. 2024). Released antigens are captured and gradually released by the mesoporous structure, maintaining high local antigen concentrations (Fig. 2). This process leads to dendritic cell activation and macrophage polarization toward the M1 subtype, enhancing CD8+T-cell responses and antitumor effects in both primary and distant tumors.

Open in a separate window

Fig. 2

Schematic Illustration of the ISV Fabrication of ¹⁷⁷Lu/Mn-HAP for Sustainable Antitumor Immune Response. (A) Sustained tumor antigen capture and release of ¹⁷⁷Lu/Mn-HAP. (B) Activation of systemic antitumor immune response by ¹⁷⁷Lu/Mn-HAP. Reprinted from Xu P et al. Radioactive Hydroxyapatite Microspheres Empower Sustainable In Situ Tumor Vaccination. ACS Nano 2024: 18,425–18,443

The cyclic GMP-AMP synthase (cGAS) agonist Mn²+, used as an immune adjuvant, further amplifies dendritic cell maturation and macrophage polarization, activating the cGAS-stimulator of interferon genes signalling pathway (Wang et al. 2018).

Comprehensive characterization confirmed the successful loading and release of lutetium-177 and Mn²+ by the ¹⁷⁷Lu/Mn-HAP microspheres. Cellular experiments and proteomic analyses demonstrated their ability to induce tumor cell death and capture released antigens, promoting ICD. In vitro studies revealed that ¹⁷⁷Lu/Mn-HAP stimulates dendritic cells and shifts macrophages toward an M1 polarization state.

In tumor-bearing mice, intratumorally injected ¹⁷⁷Lu/Mn-HAP achieved a 100% complete remission rate, activating systemic immunity and fostering immune memory, thus preventing tumor recurrence. In vivo SPECT/CT imaging showed stable retention at the tumor site, minimizing radiation damage to surrounding tissues.

By using composite radioactive microparticles, this study highlights a universal and safe ISV strategy capable of inducing potent tumor-specific and sustainable immune responses.

Development of potential radiopharmaceuticals directed towards multiple molecular targets: a step forward in personalized oncological theranostics?

By Ana Rey

Cancer is a complex disease comprising many subtypes with significant molecular differences. Subpopulations of cells with different biological behavior can coexist within a primary tumor and its metastasis, or in tumors of the same histopathological subtype. Furthermore, molecular targets within a tumor may change in different stages of the disease or be affected by the therapy.

Peptide-based radiopharmaceuticals have been very successful in targeting the tumor cells while sparing the normal ones. The traditional approach is to design monovalent radiotracers directed towards only one receptor overexpressed in the specific type of tumor. However, a new paradigm has arisen recently, the multivalent approach in which a heterodimeric radioligand can bind simultaneously to two different molecular targets of the cancer cell. This new concept offers a versatile solution to overcome the heterogeneous nature of tumors and holds promise for personalized care in oncology.

A recent publication presents a thorough review of the state of the art in the design of dual receptor targeting radiopharmaceuticals (Chambers et al. 2024). Many efforts have been dedicated to the combination of RGD peptides directed to the integrin α_Vβ₃ with different peptides (bombesin, alpha-melanocyte-stimulating hormone or somatostatin analogs) and PSMA inhibitors, highlighting the importance of angiogenesis and other processes associated with the extracellular matrix for molecular imaging and targeted therapy. Despite the inherent challenges associated with the synthesis of heterobivalent radioligands the results are promising in terms of enhanced sensitivity and potential to encompass a wider range of patients.

Improving the in vivo stability of [⁵²Mn]Mn(II) complexes with 18-membered macrocyclic chelators for PET imaging

By Silvio Aime

Manganese is a promising metal for both MRI and PET applications. One of the proposed manganese radioisotopes for PET imaging is manganese-52 (⁵²Mn, t_1/2 = 5.6 days), a cyclotron produced, long-lived positron emitter that can be used to obtain high-resolution images several days after injection. Two promising Mn(II)-complexes with 18-membered macrocycles PYAN (a) and CHXPYAN (b) have been investigated for their potential in vivo applications (Harriswangler et al. 2024) (Fig. 3).

Open in a separate window

Fig. 3

Two Mn(II)-complexes with 18-membered macrocycles PYAN (a) and CHXPYAN (b)

The coordination polyhedra around the Mn(II) ions can be described as severely distorted octahedra. The redox properties suggest that these Mn(II)-complexes are resistant to oxidation in biological media. The stability constants of [Mn(CHXPYAN)]²⁺ is slightly higher than that of [Mn(PYAN)]²⁺, but both complexes have higher logK_MnL values than parent [Mn(18-ane-N₆)]²⁺ indicating the improved thermodynamic properties of Mn(II) complexes with pyridyl and cyclohexyl units in the backbone. The relaxivity is fairly constant in the pH range of 6−9 with values typical of outer-sphere systems. The kinetic inertness has been assessed by following the transmetalation of [Mn(CHXPYAN)]²⁺ and [Mn(PYAN)]²⁺ with Cu²⁺. Mechanism implies the rate determining acid catalyzed dissociation (k₁) of the Mn(II) complexes followed by the fast reaction between the free ligands and the Cu²⁺ ion. The value of k₁ determined for [Mn(CHXPYAN)]²⁺ is 3600 times lower than that determined for [Mn(PYAN)]²⁺, highlighting the beneficial impact of the rigid cyclohexyl units on the kinetic inertness of the Mn(II)-complex. Human and mouse serum stability of [⁵²Mn(CHXPYAN)]²⁺ showed a 98% intact complex at 5 days post incubation. In vivo studies were carried out with a comparison to the biodistribution of uncomplexed ⁵²MnCl₂. [⁵²Mn(CHXPYAN)]²⁺ showed a different biodistribution profile as compared with that of free ⁵²Mn(II) with fast clearance from the liver and kidneys 1.5 h post-injection. Vice versa [⁵²Mn(PYAN)]²⁺ showed a similar distribution pattern as compared with that of unchelated ⁵²Mn(II) with persistent accumulation of radioactivity in the liver, pancreas, and spleen. In summary this work showed that CHXPYAN is a very promising platform for the development of ⁵²Mn(II)-based radiopharmaceuticals. Comparison of the Mn(II) complex of this chelator with that of its more flexible analogue, PYAN, shows that the incorporation of two cyclohexyl units into the 18-membered backbone confers increased thermodynamic stability and kinetic inertness. This work is an important contribution to the development of new bifunctional systems for ⁵²Mn(II)-based radiopharmaceuticals.

Quality control of actinium-225 radiopharmaceuticals: let us isolate the ²²¹Fr gamma photons for the measurement

By Pillai M.R. Ambikalmajan

Quality control of radiopharmaceuticals labeled with actinium-225 (²²⁵Ac) is a challenging task due to the presence of multiple radionuclides in its decay chain. All these radionuclides are in secular equilibrium with ²²⁵Ac and will therefore be present in the sample. To determine the radiochemical purity (RCP), it is essential to account for both the ²²⁵Ac bound to the targeting molecule through a chosen complexing agent and the unbound (free) ²²⁵Ac. A reliable method for accurate quality control of ²²⁵Ac-radiopharmaceuticals was recently described by Hooijman et al. (2024).

In this publication, rapid quality control tests followed by gamma counting are used to estimate the radiochemical yield (RCY) and RCP. There are three gamma emissions in the ²²⁵Ac decay chain, originating from ²²⁵Ac, francium-221 (²²¹Fr), and bismuth-213 (²¹³Bi), respectively. The authors measured gamma photons from ²²¹Fr or ²¹³Bi, ensuring that the counted activity corresponded to ²²⁵Ac.

Francium-221 and ²¹³Bi are radiometals and are expected to coordinate with the complexing agent in the targeting molecule. Therefore, ²²¹Fr- and ²¹³Bi-labeled variants will be present alongside the respective ²²⁵Ac-radiopharmaceutical. Uncomplexed ²²⁵Ac, ²²¹Fr, and ²¹³Bi will also be present in the free component. Counting the chromatography strip immediately after development would thus yield inaccurate results.

The decay of initially present ²²¹Fr and ²¹³Bi is shown with dotted lines, while the growth of ²²¹Fr and ²¹³Bi due to ²²⁵Ac decay is indicated with solid lines in Fig. 4. The half-life of ²²¹Fr is 4.8 min, so after 30 min, the initially present ²²¹Fr would have completely decayed. However, ²²¹Fr generated from ²²⁵Ac decay will reach secular equilibrium by around 30 min. By adopting this method, RCP can be estimated, allowing the radiopharmaceutical to be released for patient use.

Open in a separate window

Fig. 4

Presence of ²²¹Fr and ²¹³Bi in different chemical forms after ²²⁵Ac-labelling of PSMA-I&T resulting in [²²⁵Ac]Ac-PSMA-I&T. From: Hooijman EL, Radchenko V, Ling SW, Konijnenberg M, Brabander T, Koolen SLW, de Blois E. Implementing ²²⁵Ac-labelled radiopharmaceuticals: practical considerations and (pre-) clinical perspectives. EJNMMI Radiopharm Chem 2024;9:9

Bismuth-213 will reach equilibrium after 4–5 h, allowing gross gamma photon counting from ²²¹Fr and ²¹³Bi to provide a more accurate estimation of the RCP. Gamma counting can then be performed with a larger energy window to capture both emissions. The results from this measurement will provide an even more reliable estimation of the RCP.

New ¹⁸F-prosthetic group, new possibilities

By Ines Farinha Antunes

Protein-based molecules against cancer biomarkers such as receptor tyrosine kinases (HER2, EGFR), integrin αvβ3, and interleukin-2 have been explored since they possess desirable properties such as high in vivo target affinity and selectivity. Additionally, in contrast to big proteins (antibodies), they have short biological half-lives that are highly compatible with a short-lived PET radionuclide such as fluorine-18. However, the incorporation of fluorine-18 into heat-sensitive proteins remains a challenge for radiochemists. Thus, proteins are often radiolabelled indirectly using ¹⁸F-prosthetic groups such as N-succinimidyl-4-[¹⁸F]fluorobenzoate ([¹⁸F]SFB) or N-[2-4-[¹⁸F]fluorobenzamido)-ethyl]maleimide ([¹⁸F]FBEM) that conjugate respectively to the lysine or the cysteine present in the protein. These indirect radiolabelling procedures are often complex (multi-step), time-consuming, and with relatively low RCY.

A new ¹⁸F-prosthetic group, [¹⁸F]fluorophenylglyoxal ([¹⁸F]FPG) has been developed that chemoselectively conjugates to arginine residues in proteins such as human serum albumin (HSA), ubiquitin, interleukin-2 (IL2) and interleukin-4 (IL4) with 30–60% activity yield (Sadasivam et al. 2024) (Fig. 5). [¹⁸F]FPG-HSA remains stable in vitro but also in vivo leading to less defluorination (2–6%) when compared to [¹⁸F]FBA-HSA (8–10%). The [¹⁸F]FPG-HSA indicated prolonged blood retention in mice proving that the addition of the radioactive prosthetic group did not alter the biological properties of HSA. The preservation of affinity in the ¹⁸F-radiolabelled cytokines (IL2 and IL4, respectively) was also confirmed in vitro. This study has proved that [¹⁸F]FPG is a suitable alternative to radiolabel small proteins as long as the protein is not pH-sensitive and its arginine groups are not involved directly in the binding to the receptor.

Open in a separate window

Fig. 5

Synthesis of [¹⁸F]fluorophenylglyoxal and its conjugation to an arginine moiety of a protein. With permission from: Sadasivam P, Khanapur S, Harthimath SV, Ramasamy B, Cheng P, Feng CZ, Green D, Davis C, Goggi JL, Robins EG, Yan R. Arginine-Selective Bioconjugation Reagent for Effective ¹⁸F-labeling of Native Proteins. J Med Chem 2024;67:5064–5074

Unlocking the potential of combined radionuclide and immunotherapy

By Frederik Cleeren

Immune checkpoint inhibitors (ICIs) often fail in treating advanced clear cell renal cell carcinoma (ccRCC), prompting the need for improved strategies. Therefore, the potential of combining targeted radionuclide therapy (TRT) with ICIs to enhance treatment efficacy was explored (Kleinendorst et al. 2024). Researchers used [¹⁷⁷Lu]Lu-DOTA-hG250, targeting the overexpressed carbonic anhydrase IX (CAIX) in ccRCC, in combination with anti-PD-1 and anti-CTLA-4 ICIs.

The biodistribution of [¹⁷⁷Lu]Lu-DOTA-hG250 was tested in mice with Renca-CAIX or CT26-CAIX tumors, which differ in T-cell infiltration and PD-L1 expression. Tumor-absorbed radiation doses were measured, and the efficacy of TRT with and without ICI was assessed by monitoring tumor growth and survival. Tumor tissues were analyzed before and after treatment using immunohistochemistry, flow cytometry, and RNA profiling. Results showed high uptake of [¹⁷⁷Lu]Lu-DOTA-hG250 in both tumor models. Dose escalation studies in Renca-CAIX mice demonstrated that [¹⁷⁷Lu]Lu-DOTA-hG250 had a dose-dependent anti-tumor effect. Combining a subtherapeutic TRT dose (4 MBq) with ICIs resulted in remarkable synergy and complete remissions. Similar results were observed in the CT26-CAIX model. Ex vivo analyses revealed DNA damage, increased T-cell infiltration, and modulated immune signaling pathways in the tumor microenvironment following combination treatment.

This proof-of-concept study demonstrates the outstanding therapeutic efficacy of combining subtherapeutic [¹⁷⁷Lu]Lu-DOTA-hG250 with ICIs, leading to complete remissions and durable memory immune responses. These findings highlight the potential of combined TRT/ICI therapy for advanced ccRCC, providing insights for further mechanistic preclinical studies and paving the way for future clinical trials to maximize treatment benefits for patients.

An old dog with new tricks: ⁶⁸Ga-FAPI-04-PET for monitoring tumor responses to immunotherapy combinations in metastatic colorectal cancer

By Zhaofei Liu

Fibroblast activation protein (FAP)-targeted PET has been extensively investigated in clinical studies for the detection of various tumors and metastases. However, its utility in tracking tumor responses to inform precision therapies is limited. FAP is upregulated in cancer-associated fibroblasts, which produce immunosuppressive factors such as transforming growth factor-β (TGF-β), creating an immunosuppressive tumor microenvironment that can confer resistance to immunotherapy. It was shown that FAP-targeted PET with ⁶⁸Ga-FAPI-04 can assess the effectiveness of combining TGF-β receptor (TGF-βR) inhibition with immune checkpoint blockade in metastatic colorectal cancer (Li et al. 2024). The trial involving 131 patients revealed that ⁶⁸Ga-FAPI-04-PET provided complementary information to ¹⁸F-FDG-PET for cancer detection. Tumor tissue staining indicated that ⁶⁸Ga-FAPI-04-PET could identify the immunosuppressive tumor microenvironment, which may act as a biomarker predicting tumor resistance to immunotherapy in patients. Following this, the authors turned to animal studies to assess the effectiveness of ⁶⁸Ga-FAPI-04-PET in monitoring tumor responses to the combination immunotherapy of TGF-βR inhibition and a bispecific antibody targeting both PD-L1 and CTLA-4 in colorectal cancer metastasis models. The findings highlighted the sensitivity of ⁶⁸Ga-FAPI-04-PET in monitoring tumor responses to the combined immunotherapy, potentially expanding the clinical role of FAP-targeted PET beyond tumor detection. Since FAP is also overexpressed in other disorders such as sclerosis, amyloidosis, and myocardial infarction, this study paves the way for FAP-targeted PET to guide personalized therapies for a broader spectrum of diseases.

⁶⁸Ga-labelled peptide CK2 for PET imaging of NRP-1 expression

By Beverley Ellis

Neuropilin-1 (NRP-1) is a multifunctional glycoprotein which can be overexpressed in many cancer cells. It has been identified an effective target for the diagnosis and treatment of breast cancer, especially triple-negative breast cancer TNBC. NRP-1 targeting peptide radiotracers generally exhibit good biological properties but may have drawbacks of relatively poor stability, rapid clearance, and low permeability.

A novel NRP-1 peptide CK2 was designed and validated using in silico modelling and microscale thermophoresis assay with a view to improving the sensitivity and specificity detecting NRP-1 expression using PET imaging (Liu et al. 2024). [⁶⁸Ga]Ga-NOTA-PEG₄-CK2 was synthesized with a high radiochemical yield and showed high in vitro stability. In vitro and in vivo studies were undertaken to assess the specificity and sensitivity of this radiotracer.

In vitro cellular uptake assay demonstrated that the radiotracer specifically binds to NRP-1 positive cancer cells (MDA-MB-231) rather than NRP-1 negative cancer cells (NCI-H1299). MicroPET imaging showed a significant accumulation of [⁶⁸Ga]Ga-NOTA-PEG₄-CK2 in MDA-MB-231 tumors compared with NCI-HI299 tumors. High specificity of [⁶⁸Ga]Ga-NOTA-PEG₄-CK2 for NRP-1 expression was also confirmed by ex vivo biodistribution, autoradiography, western blot and immunofluorescence staining. The expression of NRP-1 in MDA-MB-231 tumors and cells was shown to be down-regulated by SB-203,580 treatment which could be sensitively monitored by [⁶⁸Ga]Ga-NOTA-PEG₄-CK2. The authors conclude that [⁶⁸Ga]Ga-NOTA-PEG₄-CK2 is a promising new radiotracer for the detection NRP-1 expression and could provide useful information for evaluating the prognosis of breast cancer.

Peptidoglycan-targeting radiotracers for bacteria-specific imaging

By Maryke Kahts

Infection and antimicrobial resistance have been major topics of discussion in recent years, with continuous global efforts focused on preserving antibiotic efficacy. Among these efforts is the early identification and localization of the causative bacterial pathogen to initialize the most appropriate treatment regimen as soon as possible. All existing infection detection methods have their respective limitations. Current nuclear medicine imaging approaches utilize radiopharmaceuticals that lack specificity for infection, e.g. [¹⁸F]fluorodeoxyglucose and radiolabeled leukocytes. Bacteria-specific radiotracers have therefore emerged as a hot topic. The peptidoglycan layer in the bacterial cell wall offers the potential to develop radiotracers that can accurately and specifically detect infection and possibly distinguish between Gram-negative and Gram-positive bacterial strains.

Recent investigations on radiotracers targeting peptidoglycan biosynthesis were summarized (Koatale et al. 2024) (Fig. 6). Some promising radiotracers identified are amino acid-based tracers, e.g. D-[¹¹C]methionine, D-[¹¹C]alanine and D-[¹¹C]glutamine, D-amino acid dipeptide-based probes, e.g. D-[¹¹C]alanyl-D-alanine, Park’s nucleotide-based probes, e.g. UDP-MurNAc-[¹¹C]pentapeptide, lipid-based probes, e.g. [¹¹C]GlcNAc-labeled lipid II, glycan core-based probes, e.g. [³H]acetylglucosamine and [¹⁸F]fluoroacetamido-D-glucopyranose, and oligopeptide-based probes, e.g. L-ala-D-glu-[³H]A2pm. Specifically, D-[¹¹C]methionine illustrated promising clinical application in suspected prosthetic joint infections and D-[¹¹C]alanine in spinal infections, pneumonia and antibiotic-resistant infections.

Open in a separate window

Fig. 6

Proposed pathways of peptidoplycan biosynthesis and potential precursors for designing radiotracers or probes from imaging. With permission under licence CC BY 4.0 from Koatale P, Welling M, Ndlovu H, Kgatle M, Mdanda S, Mdlophane A, Okem A, Takyi-Williams J, Sathekge M, Ebenhan T. Insights into Peptidoglycan-Targeting Radiotracers for Imaging Bacterial Infections: Updates, Challenges, and Future Perspectives. ACS Infectious Diseases 2024;10:270–286

The limitations in developing peptidoglycan biosynthesis-targeting radiotracers were also highlighted, including complex chemical synthesis, the challenging radiochemistry of fluorine-18 and carbon-11, cyclotron production of these radionuclides, and the associated cost and sophistication of the required infrastructure (Koatale et al. 2024). The authors concluded that technological innovation in biology, chemistry and radiochemistry, with a multidisciplinary approach is needed for clinically translatable research in this field.

Latest trends on radiopharmaceuticals for bacterial infection imaging

By Fany Pricile Ekoume

Appropriate therapies with a high rate of antimicrobial resistance is a great concern in African hospitals (Ngogang et al. 2024). The same trend is observed worldwide with the prediction that the major cause of death by 2050 would be drug resistant infections. To overcome the threat posed by antimicrobial resistance to the health care system, factors including personalized medicine utilizing radionuclide imaging with fast and accurate diagnosis of infections and reliable identification of intractable and resistant infection are crucial for the application of antibiotic stewardship and the overuse of broad-spectrum antibiotics (Kahts et al. 2024). Nowadays, the development and investigation of new radiopharmaceuticals based on differentiation of infection from sterile inflammation as well as the imaging of specific infectious microbes’ processes using both PET and SPECT products could help to approach the issue in a holistic manner.

A recent review of the most prominent discoveries related to radiopharmaceuticals development and characterization of bacterial infection imaging agents includes radiolabelled bacterial siderophores to target E. coli-induced infections. More so, fungal siderophores were studied using small animal PET imaging in a mouse model of infection and achieving RCP higher than 95% (Krasulova et al. 2024). Moreover, antimicrobial peptides labelled with ⁶⁴Cu, ⁶⁸Ga, and ^99mTc was documented as well as several radiolabelled antibiotics investigations performed. The preferred tracer would be dependent on the clinical scenario, with consideration of its ability firstly, to detect all or most pathogenic microorganisms, secondly to distinguish infection from other processes, lastly to play a role to identify specific bacterial strains for the selection of the most appropriate and effective antimicrobial therapy. Selected radiopharmaceuticals were highlighted with regard to on one hand, their promising first-in-human application, on the other hand, significant results from well-structured conceptional clinical investigations in small patient populations, and ultimately, on evidence from early clinical trials.

The authors conclude that the key to reliable evaluation of the true potential of the newly proposed infection imaging agents include a more structured and harmonized preclinical setting as well as well-designed clinical investigations (Kahts et al. 2024).

New options for treating patients with NETs

By Ivis F Chaple

Recent advances in Somatostatin Receptor (SSTR)-targeted diagnostic and therapeutic radiopharmaceuticals have resulted in clinical indications for patients with SSTR positive Neuroendocrine Tumors (NETs). The importance of continued research and development for NET imaging and targeted therapy was recently demonstrated (Gomes et al. 2024). This article highlights the need to perform dosimetry computations to generate estimated organ absorbed dose for all radiopharmaceuticals, to ascertain safety profiles and feasibility for clinical translation, particularly when options already exist in the clinical space. Performing dosimetry computations for radiopharmaceuticals prior to pursuing clinical translation efforts could lead to emphasise on studying modifications of peptides for improved receptor specificity and pharmacokinetic profiles. The study further improves the landscape for radiopharmaceuticals targeting SSTR+NETs by providing absorbed dose estimates for [^43/44/44mSc]Sc-DOTA-TATE compared to the Food and Drug Administration (FDA) approved [⁶⁸Ga]Ga-DOTA-TATE and ¹¹¹In-Octreotide. It was concluded that their data indicate a reasonably higher absorbed dose per injected activity of [^43/44/44mSc]Sc-DOTA-TATE in organs at risk as compared to the dose delivered by [⁶⁸Ga]Ga-DOTA-TATE. However, this assumes that both radiopeptides distribute equally in the body. The calculated doses are within a reasonable order of magnitude of other clinically used radionuclides, indicating feasibility of employing [^43/44/44mSc]Sc-DOTA-TATE for PET imaging of SSTR+NETs. Implementation of [^43/44/44mSc]Sc-DOTA-TATE as diagnostic imaging options for patients could prove beneficial due to the more similar chemical characteristics of Sc (compared to Ga) and Lu, of which ¹⁷⁷Lu is currently employed for targeted therapy of SSTR+NETs. The suggestion of utilizing radioscandium provides an important discussion on research and development in the areas of exotic radionuclide implementation, as they could provide enhanced radiochemistry capabilities and, ultimately, serve as better pairs for some therapeutic counterparts.

Towards a microfluidic synthesis of PET radiopharmaceuticals

By Emerson Bernardes

Outside the academic sphere, innovative concepts often materialize through the establishment of startups. These new companies are founded by one or more entrepreneurs who aim to develop a product or service they perceive to have market demand. However, the most frequent cause of startup failure is the absence of a market need for the offered product or service, which indicates the solution provided is not compelling enough for customers to invest in – simple as that.

In academia, the development of integrated and automated microfluidic platforms for radiotracer production is ongoing, focusing on new methods to avoid azeotropic drying and creating automated systems that interface with existing production methods and comply with GMP standards (Ovdiichuk et al. 2024). However, the expected demand for these technologies in the radiopharmaceutical market has not yet materialized as anticipated. Experts in the field argue that: (1) implementing microfluidic systems for radiopharmaceutical production is crucial for enabling personalized care through dose-on-demand radiotracer production; and (2) the high cost of radiotracer synthesis and the necessity for highly trained operators to manage commercial equipment are major factors preventing the introduction of new PET radiopharmaceuticals and the reason why [¹⁸F]FDG remains the predominant choice, accounting for over 95% of procedures (McVeigh and Bellan 2024). Therefore, shifting from multi-dose to single-dose batches would enable hospitals and nuclear medicine centers to reduce costs and manufacture other non-commercialized PET radiopharmaceuticals.

Reflecting on over two decades of microfluidic platform development, the integration of this technology into the radiopharmaceutical market seems increasingly inevitable. Perhaps, the key question is not whether microfluidics will be adopted, but in which segment of the radiopharmaceutical market it will have the most significant impact. The new microfluidic platforms and methods are well-suited for: (1) small-scale commercial manufacturing of numerous new radiopharmaceuticals currently under evaluation or soon to be evaluated in clinical trials; (2) production of short-lived PET radionuclides, such as ¹⁵O (t_1/2 = 2 min), ¹³N (t_1/2 = 10 min), and ¹¹C-based radiopharmaceuticals, for research purposes in academic institutions; (3) supporting the research and development of novel radiopharmaceuticals in non-clinical stage; and (4) purification of radionuclides.

At present, there is no global movement towards dose-on-demand in the radiopharmaceutical market, and the cost of radiopharmaceutical production is not a significant obstacle to the widespread adoption of new radiopharmaceuticals beyond ¹⁸F-FDG. A key reason why new tracers do not achieve widespread use is not necessarily the production cost, but rather the absence of clear, patient-relevant clinical outcomes. Ultimately, if the benefits for patients are not compelling, there will be no demand for the new tracers.

If there is no market demand for a product or service, startups typically fail and disappear, either before they exhaust their funds or soon after, with financial depletion being the second most common reason for startup failures. Unfortunately, in academia, once misleading information and unrealistic expectations about the widespread adoption of microfluidic platforms for radiopharmaceutical production are published, they tend to persist without contributing to the field’s development.

Peptide binder to glypican-3 as a theranostic agent for hepatocellular carcinoma

By Martin Behe

The authors describe the evaluation of a radiolabeled bicyclic peptide targeting Glypican-3 (Lin et al. 2024). Glypican-3 is involved in embryonic development with a low level of expression in healthy tissue after birth. But it is highly expressed in tumors like hepatocellular carcinoma (HCC), lung adenocarcinoma, squamous cell carcinoma, embryonal tumors, testicular germ cell tumors, and liposarcoma. Therefore, it is a highly interesting target for radioligand therapy.

The authors evaluated a DOTA coupled bicycle peptide (RAYZ-8009) which was identified with a peptide library screen with actinium-225 and lutetium-177 (Fig. 7). A saturation binding assay with [¹⁷⁷Lu]Lu-RAYZ-8009 revealed a dissociation constant of 10.8 nM. Inhibitory binding assays showed no significant differences between different isotopes (lanthanum were used as a surrogate for actinium).

Open in a separate window

Fig. 7

Graphical abstract of the biological evaluation of the peptide binder to glypican-3. This research was originally published in JNM. Fanching Lin, Renee Clift, Takeru Ehara, Hayato Yanagida, Steven Horton, Alain Noncovich, Matt Guest, Daniel Kim, Katrina Salvador, Samantha Richardson, Terra Miller, Guangzhou Han, Abhijit Bhat, Kenneth Song and Gary Li. Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. J Nucl Med. 2024;4:586–592. © SNMMI

The biodistribution study in mice bearing a tumor derived from HepG2 (human HCC cell line) showed a high uptake in the receptor positive tumor with a slow release (lutetium-177, 1 h: 25% i.a./g; 96 h: 8.8% i.a./g). The kidneys are the only organs with significant uptake but they exhibit a fast clearance (1 h: 20% i.a./g; 96 h: 0.67% i.a./g). Therapeutic studies with actinium-225 and lutetium-177 radiolabeled RAYZ-8009 with two different HCC tumors xenografts showed a significant reduction of tumor growth with even a complete remission with 111 kBq [²²⁵Ac]Ac-RAYZ-8009 in Hep3B xenografts.

Overall this is a very nice example of a radioconjugate derived from a library screening with a highly promising preclinical evaluation and high potential in clinical applications. A weakness of the paper is that the structural information is missing which are highly necessary to completely understand the results from a scientific point of view.

Novel combination strategy for ¹⁷⁷Lu-labelling of antibody under mild condition

By Ya-Yao Huang

To develop an approach with both advantages of radiometal-chelation under mild conditions and rapid antibody-conjugation is important for radioimmunotherapy. The novel nonadecadentate bispidine (Bisp, 3,7-diazabicyclo[3.3.1]nonane) has been shown the ability to achieve coordinatively saturated lanthanide (III)-protein complexes with high thermodynamic and kinetic stability (Cieslik et al. 2022). On the other hand, one-pot photochemical antibody-conjugation methods have successfully been applied in ⁶⁸Ga-labeled antibodies with the chelator bearing a photoactivatable ArN₃ group (Patra et al. 2019; Fay et al. 2019). Two approaches above were recently combined to conduct the [¹⁷⁷Lu]Lu-Bisp-ArN3 chelation at 40 for 10 min and following photo-conjugation of Trastuzumab at 23 °C/395 nm for 15 min, and successfully achieved final product of [¹⁷⁷Lu]Lu-Bisp-Trastuzumab with 12–14% of decay-corrected radiochemical yield and >90% of radiochemical purity (Cieslik et al. 2024). However, low radioactivity concentration may cause the lower tumor uptake compared to ⁸⁹Zr-labelled Trastuzumab (i.e., 30% vs. 66%). In particular, the stability of [¹⁷⁷Lu]Lu-Bisp-Trastuzumab in human serum may be concerned for the clinical use, because of the degradation after 24 h even under low radioactivity concentration.

The in vivo stability depending on the radioactivity concentration has been defined as a key parameter during the development of ¹⁷⁷Lu-labeled radiopharmaceuticals, especially when high levels of [¹⁷⁷Lu]LuCl₃ activity (>1GBq) is commonly used in a clinical setting. Consequently, the feasibility of fully automated radiosynthesis of [¹⁷⁷Lu]Lu-Bisp-Trastuzumab using the custom-built ALISI device (Klingler et al. 2022) and the role of different radiolysis quenchers both warrant further investigation (Larenkov et al. 2023; Schmitl et al. 2023).

Cholecystokinin-2 receptor targeting with theranostic potential

By Renata Mikolajczak

Recently published as the EJNMMI image of the month, cholecystokinin-2 receptor (CCK2R) targeting by [⁶⁸Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancer (Di Santo et al. 2024) provides an excellent opportunity to highlight the role gastrin/cholecystokinin-2 receptors as molecular targets.

CCK2 receptors are expressed at high incidence in medullary thyroid carcinomas (MTC, > 90%), small cell lung cancers (>50%), astrocytomas (>60%), insulinomas, stromal ovarian cancers, gastrointestinal stromal tumors, and more than 20% of gastroenteropancreatic tumors (Reubi et al. 1997). Although the CCK2R-targeting peptide probes are based on the natural ligands cholecystokinin and gastrin, the high kidney uptake and the limited enzymatic stability of these linear peptide analogues in vivo created a challenge for researchers. DOTA-MGS5 (DOTA-d-Glu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH₂) proposed by the Innsbruck group in 2019 was among the newest minigastrin analogues with an optimized targeting profile (Klingler et al. 2019). In preclinical studies, it demonstrated a high and persistent tumor uptake and favourable tumor-to-background activity ratios, including kidneys.

To date, only a few CCK2 receptor-targeting radioligands have been used in a clinic with a focus on MTC patients. [⁶⁸Ga]Ga-DOTA-MGS5 showed high uptake in all FDG-avid lesions and identified additional abnormal foci in the patient with advanced small cell lung cancer, suggesting disease progression (Di Santo et al. 2024). Since DOTA-MGS5 can also be labelled with ¹⁷⁷Lu, the CCK2 receptor targeting can be considered for therapy. These promising findings encourage further clinical studies oriented at the CCK2 receptor targeting of advanced-stage CCK2R-expressing malignancies.

Revolutionizing radiochemistry: high-throughput experimental approach for efficient cu-mediated ¹⁸F-radiofluorination

By Shozo Furumoto

High-throughput experimentation (HTE) has revolutionized drug discovery by enabling rapid identification of promising compounds and efficient optimization of reaction conditions. However, its application to radiolabeled drug development, particularly for PET radiopharmaceuticals, has been underutilized. Recently, the groups of Melanie S. Sanford and Peter J. H. Scott introduced a novel HTE platform for copper-mediated radiofluorination (CMRF) of aryl boronates using ¹⁸F (Webb et al. 2024) (Fig. 8). In this study, a total of 16 different reaction conditions for 31 compounds were investigated to determine optimal labeling conditions. By integrating commercial HTE instrumentation with advanced analytical techniques-including PET scanners, gamma counters, and autoradiography (ARG)- research demonstrates significant time and cost savings while increasing the efficiency of reaction optimization. The group compared radiochemical conversion (RCC) values from PET scanners, gamma counters, and ARG with those from conventional radio-TLC, a widely used method for calculating RCC. They found that PET scanners and gamma counters showed strong correlations with RCC values from radio-TLC, confirming the reliability of these high-throughput methods. The results of this study underscore the potential for broader adoption of HTE in radiochemistry, not only for ¹⁸F but also for other radionuclides, which could accelerate the development of radiopharmaceuticals. The study also points out limitations, such as challenges in product identification and the need for further automation. However, the study provides a roadmap for future advances in high-throughput radiochemistry. Overall, this research represents a significant advance, offering both practical solutions and new directions for optimizing complex radiolabeling reactions in a more efficient and scalable manner.

Open in a separate window

Fig. 8

Schematic overview of the High Throughput Experiments by performing ¹⁸F-fluorinations in multiwell plates, with subsequent separation and analysis. With permission from Webb EW, Cheng K, Winton WP, Klein BJC, Bowden GD, Horikawa M, Liu SW, Wright JS, Verhoog S, Kalyani D, Wismer M, Krska SW, Sanford MS, Scott PJH. Development of High-Throughput Experimentation Approaches for Rapid Radiochemical Exploration. J Am Chem Soc 2024;146:10581–10590

In vivo stable ²¹¹At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure

By Amal Elrafaei

Prostate cancer is common globally (Sung et al. 2021), with metastatic castration-resistant prostate cancer (mCRPC) being hard to treat. PSMA, overexpressed in mCRPC, is a key target for targeted alpha therapy (TAT). A novel TAT by designing a stable PSMA-targeted tracer labeled with the alpha-emitting radiohalogen astatine-211 is presented, using a neopentyl glycol (NpG) structure which is being stable against dehalogenation (Suzuki et al. 2024).

The biodistribution of ²¹¹At-labeled PSMA derivatives was studied in normal and tumor-bearing mice. Results indicate [²¹¹At]At-NpG-D-PSMA shows promise as a new TAT for mCRPC due to its in vivo stability and favourable biodistribution. Comparisons with derivatives suggest that modifications, such as using a D-form glutamic acid linker, enhance in vivo stability and reduce unwanted metabolization. The findings suggest that [²¹¹At]At-NpG-D-PSMA could be a promising candidate for further mCRPC treatment development.

The study confirms that PSMA ligand derivatives with D-form amino acids, show higher tumor accumulation than those with L-form amino acids, consistent with previous findings (Weineisen et al. 2014). The configuration of the glutamic acid linker affects renal retention, with D-form linkers having shorter retention times in the kidney compared to L-form linkers.

This study observed that the NpG structure effectively retains astatine-211 in vivo, as shown by low accumulation in the stomach and thyroid. [²¹¹At]At-NpG-D-PSMA maintained stable tumor radioactivity with decreased renal radioactivity over time, making it a promising candidate for TAT in mCRPC due to its favourable biodistribution, stability, and tumor accumulation.

Philip H. Elsinga, Klaus Kopka and Peter J. H. Scott did follow-up editing.